DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones

被引：50

作者：

Bébéar, CM ^{[1
]}

Renaudin, H ^{[1
]}

Charron, A ^{[1
]}

Clerc, M ^{[1
]}

Pereyre, S ^{[1
]}

Bébéar, C ^{[1
]}

机构：

[1] Univ Bordeaux 2, Bacteriol Lab, F-33076 Bordeaux, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 10期

关键词：

D O I：

10.1128/AAC.47.10.3323-3325.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Twelve clinical isolates of Ureaplasma spp. and one isolate of Mycoplasma hominis were examined for resistance to fluoroquinolones. Previously described mutations at positions 83 and 95 in GyrA (Escherichia coli numbering) and positions 80 and 87 in ParC were found. Unusual alterations were described at positions ParC 123 and 134.

引用

页码：3323 / 3325

页数：3

共 14 条

[1] Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease [J].

AbeleHorn, M ;

Wolff, C ;

Dressel, P ;

Pfaff, F ;

Zimmermann, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (05) :1199-1202

[2] Septic arthritis due to Ureaplasma urealyticum:: concerning one case [J].

Abraham, B ;

Leclercq, C ;

Bébéar, C ;

Renaudin, H ;

Janbon, F .

MEDECINE ET MALADIES INFECTIEUSES, 2001, 31 (06) :453-454

[3] Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].

Bast, DJ ;

Low, DE ;

Duncan, CL ;

Kilburn, L ;

Mandell, LA ;

Davidson, RJ ;

de Azavedo, JCS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054

[4] Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis [J].

Bebear, CM ;

Renaudin, J ;

Charron, A ;

Renaudin, H ;

de Barbeyrac, B ;

Schaeverbeke, T ;

Bebear, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :954-956

[5] Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro [J].

Bébéar, CM ;

Renaudin, H ;

Charron, A ;

Bové, JM ;

Bébéar, C ;

Renaudin, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2304-2311

[6] In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized [J].

Bebear, CM ;

Renaudin, H ;

Charron, A ;

Gruson, D ;

Lefrancois, M ;

Bebear, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2557-2560

[7]

Blanchard A, 2002, MOL BIOL PATHOGENICI, P45

[8] Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance [J].

Hooper, DC .

CLINICAL INFECTIOUS DISEASES, 1998, 27 :S54-S63

[9] Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus:: Novel mutations suggest novel drug-target interactions [J].

Ince, D ;

Hooper, DC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3344-3350

[10] Species identification and subtyping of Ureaplasma parvum and Ureaplasma urealyticum using PCR-based assays [J].

Kong, FR ;

Ma, ZF ;

James, G ;

Gordon, S ;

Gilbert, GL .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (03) :1175-1179

← 1 2 →